MX2009007784A - Composiciones de tiacumicinas estables. - Google Patents

Composiciones de tiacumicinas estables.

Info

Publication number
MX2009007784A
MX2009007784A MX2009007784A MX2009007784A MX2009007784A MX 2009007784 A MX2009007784 A MX 2009007784A MX 2009007784 A MX2009007784 A MX 2009007784A MX 2009007784 A MX2009007784 A MX 2009007784A MX 2009007784 A MX2009007784 A MX 2009007784A
Authority
MX
Mexico
Prior art keywords
tiacumicins
compositions
stable
formulations
difimicin
Prior art date
Application number
MX2009007784A
Other languages
English (en)
Spanish (es)
Inventor
Suketu Sanghvi
Mark Roach
Michael Mittleberg
Ping He
Joseph F Zhou
Original Assignee
Optimer Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Optimer Pharmaceuticals Inc filed Critical Optimer Pharmaceuticals Inc
Publication of MX2009007784A publication Critical patent/MX2009007784A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C07H17/08Hetero rings containing eight or more ring members, e.g. erythromycins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12Antidiarrhoeals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
MX2009007784A 2007-01-19 2008-01-17 Composiciones de tiacumicinas estables. MX2009007784A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US88113707P 2007-01-19 2007-01-19
PCT/US2008/000591 WO2008091518A1 (en) 2007-01-19 2008-01-17 Compositions of stable tiacumicins

Publications (1)

Publication Number Publication Date
MX2009007784A true MX2009007784A (es) 2010-02-11

Family

ID=39641896

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009007784A MX2009007784A (es) 2007-01-19 2008-01-17 Composiciones de tiacumicinas estables.

Country Status (22)

Country Link
US (2) US20080176927A1 (enExample)
EP (1) EP2121716B1 (enExample)
JP (2) JP5635266B2 (enExample)
KR (1) KR101491729B1 (enExample)
CN (2) CN105169396A (enExample)
BR (1) BRPI0806713A8 (enExample)
CA (1) CA2676003C (enExample)
CY (1) CY1117237T1 (enExample)
DK (1) DK2121716T3 (enExample)
ES (1) ES2560669T3 (enExample)
HR (1) HRP20151438T1 (enExample)
HU (1) HUE028671T2 (enExample)
IL (1) IL199941A (enExample)
MX (1) MX2009007784A (enExample)
NZ (1) NZ578493A (enExample)
PL (1) PL2121716T3 (enExample)
PT (1) PT2121716E (enExample)
RU (1) RU2484829C2 (enExample)
SI (1) SI2121716T1 (enExample)
TW (1) TWI474820B (enExample)
WO (1) WO2008091518A1 (enExample)
ZA (1) ZA200905134B (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7906489B2 (en) 2004-05-14 2011-03-15 Optimer Pharmaceuticals, Inc. 18-membered macrocycles and analogs thereof
US7378508B2 (en) 2007-01-22 2008-05-27 Optimer Pharmaceuticals, Inc. Polymorphic crystalline forms of tiacumicin B
TWI523654B (zh) 2007-11-27 2016-03-01 默沙東藥廠 抗生素巨環化合物以及其製造及使用之方法
CA2799531A1 (en) * 2010-05-18 2011-11-24 Optimer Pharmaceuticals, Inc. Treating recurring clostridium difficile infection using fidaxomicin
MX2012013374A (es) * 2010-05-18 2013-05-06 Optimer Pharmaceuticals Inc Tratamiento de infecciones de clostridium difficile en pacientes bajo terapia con antibioticos.
ES2654945T3 (es) * 2010-06-02 2018-02-15 Diffusion Pharmaceuticals Llc Formulaciones orales de carotenoides trans bipolares
US20140024609A1 (en) * 2011-02-04 2014-01-23 Optimer Pharmaceuticals ,Inc. Treatment of Bacterial Infections
ITMI20120560A1 (it) 2012-04-05 2013-10-06 Olon Spa Procedimento per la purificazione della tiacumicina b
JO3464B1 (ar) * 2013-01-15 2020-07-05 Astellas Pharma Europe Ltd التركيبات الخاصة بمركبات التياكوميسين
US20150141356A1 (en) * 2013-11-15 2015-05-21 Optimer Pharmaceuticals, Inc. Treatment of Clostridium Difficile Infection in High Risk Patients
WO2015127955A1 (en) 2014-02-25 2015-09-03 Olon S.P.A. A new polymorph of tiacumicin b and process for preparation thereof
DK3139932T3 (en) * 2014-05-09 2018-11-12 Astellas Pharma Europe Ltd The treatment regimen for thiacumicin compound
CN110037992B (zh) * 2019-05-28 2021-05-28 杭州华东医药集团新药研究院有限公司 一种稳定的非达霉素组合物
CN112353774B (zh) * 2020-11-17 2022-08-23 浙江汇能生物股份有限公司 一种那西肽风味咀嚼片及其制备方法及其在犬魏氏梭菌病上的用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05192094A (ja) * 1991-09-03 1993-08-03 Takeda Chem Ind Ltd 造粒組成物
US5583115A (en) * 1995-05-09 1996-12-10 Abbott Laboratories Dialkyltiacumicin compounds
WO2002032427A1 (en) * 2000-10-20 2002-04-25 Galephar M/F Stable oral formulation containing benzimidazole derivative
US20030099699A1 (en) * 2001-11-13 2003-05-29 Hanshew Dwight D. Storage stable thyroxine active drug formulations and methods for their production
WO2004014295A2 (en) * 2002-07-29 2004-02-19 Optimer Pharmaceuticals, Inc. Tiacumicin production
WO2006085838A1 (en) 2005-01-31 2006-08-17 Optimer Pharmaceuticals, Inc. 18-membered macrocycles and analogs thereof
US9211259B2 (en) * 2002-11-29 2015-12-15 Foamix Pharmaceuticals Ltd. Antibiotic kit and composition and uses thereof
CA2510465A1 (en) * 2002-12-18 2004-07-08 Pain Therapeutics Oral dosage forms with therapeutically active agents in controlled release cores and immediate release gelatin capsule coats
US7906489B2 (en) * 2004-05-14 2011-03-15 Optimer Pharmaceuticals, Inc. 18-membered macrocycles and analogs thereof

Also Published As

Publication number Publication date
EP2121716A4 (en) 2013-06-12
BRPI0806713A8 (pt) 2017-04-18
CN102015747A (zh) 2011-04-13
ES2560669T3 (es) 2016-02-22
HUE028671T2 (en) 2016-12-28
SI2121716T1 (sl) 2016-03-31
BRPI0806713A2 (pt) 2011-09-13
AU2008209623A2 (en) 2010-01-28
RU2484829C2 (ru) 2013-06-20
HRP20151438T1 (hr) 2016-01-29
TWI474820B (zh) 2015-03-01
JP5995331B2 (ja) 2016-09-21
JP2010516677A (ja) 2010-05-20
PL2121716T3 (pl) 2016-04-29
KR20090107061A (ko) 2009-10-12
EP2121716B1 (en) 2015-12-09
DK2121716T3 (en) 2016-03-14
US20080176927A1 (en) 2008-07-24
CY1117237T1 (el) 2017-04-05
WO2008091518A1 (en) 2008-07-31
EP2121716A1 (en) 2009-11-25
PT2121716E (pt) 2016-03-03
IL199941A0 (en) 2010-04-15
ZA200905134B (en) 2013-08-28
CA2676003A1 (en) 2008-07-31
JP2014205701A (ja) 2014-10-30
IL199941A (en) 2016-02-29
JP5635266B2 (ja) 2014-12-03
NZ578493A (en) 2012-02-24
US20130065844A1 (en) 2013-03-14
CA2676003C (en) 2012-04-10
RU2009128612A (ru) 2011-02-27
AU2008209623A1 (en) 2008-07-31
KR101491729B1 (ko) 2015-02-09
TW200938187A (en) 2009-09-16
CN105169396A (zh) 2015-12-23

Similar Documents

Publication Publication Date Title
MX2009007784A (es) Composiciones de tiacumicinas estables.
EP3626253A3 (en) Stable formulations of linaclotide
NZ742220A (en) Pharmaceutical compositions comprising meloxicam
UA95975C2 (ru) N-метиламинометилизоиндольные соединения, композиции, содержащие их, и способы их применения
EP4327888A3 (en) Oral formulations of cytidine analogs and methods of use thereof
TW200745078A (en) Isoindole-imide compounds and compositions comprising and methods of using the same
PH12015501523A1 (en) Formulations of 4-amino-2-(2, 6-dioxopiperidine-3-yl) isiondoline-1, 3-dione
MX2019012939A (es) Formulaciones que contienen linaclotida para administracion oral.
CR20110596A (es) Composiciones sublinguales de dexmedetomidina y métodos de uso de ellas
UA103930C2 (ru) Соединения и композиция для лечения паразитарных болезней
EA201190145A1 (ru) Фармацевтические композиции, содержащие основание прасугреля или его фармацевтически приемлемые соли присоединения кислоты, и способы их приготовления
MY150855A (en) Oral compositions containing extracts of zizyphus joazeiro and related methods
IN2012DN01233A (enExample)
EA025871B9 (ru) Ингибиторы mek и способы их применения
MY161595A (en) Oral care compositions
IN2012DN03182A (enExample)
PH12012501620A1 (en) Oral care compositions
TN2011000651A1 (en) Solid pharmaceutical fixed dose compositions comprising irbesartan and amlodipine their preparation and their therapeutic application
MY150829A (en) Oral compositions containing extracts of myristica fragrans and related methods
MX2009010174A (es) Derivados de aza-adamantano ester y carbamato y metodos de uso de los mismos.
TN2012000363A1 (en) Solid pharmaceutical formulations of ramipril and amlodipine besylate, and their preparation
EP2528440A4 (en) SUBSTITUTED NORINDEN ISOCHINOLINE, SYNTHESIS THEREOF AND METHOD OF USE THEREOF
WO2008039894A3 (en) Atorvastatin pharmaceutical compositions
PH12021550093A1 (en) Compounds for use in the treatment of fascioliasis
WO2011039675A3 (en) Latrepirdine transdermal therapeutic dosage forms

Legal Events

Date Code Title Description
FG Grant or registration